Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HEPA NASDAQ:NMTR NASDAQ:SMFL NASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEPAHepion Pharmaceuticals$0.06-29.0%$0.06$0.03▼$0.08$491K1.5272,858 shs4,517 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs14 shsSMFLSmart for Life$0.00-72.7%$0.01$0.00▼$1.28$2K17.065,858 shs508 shsSPRCSciSparc$1.81-5.7%$5.13$1.75▼$37.59$1.03M0.861.03 million shs159,865 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEPAHepion Pharmaceuticals0.00%-28.85%-7.50%-20.83%-99.85%NMTR9 Meters Biopharma0.00%0.00%0.00%-99.72%-81.82%SMFLSmart for Life0.00%-91.18%-95.16%-97.74%-99.96%SPRCSciSparc0.00%-18.83%-63.14%-73.15%-71.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHEPAHepion Pharmaceuticals$0.06-29.0%$0.06$0.03▼$0.08$491K1.5272,858 shs4,517 shsNMTR9 Meters Biopharma$0.00$0.07▼$6.56$1.04M1.36315,915 shs14 shsSMFLSmart for Life$0.00-72.7%$0.01$0.00▼$1.28$2K17.065,858 shs508 shsSPRCSciSparc$1.81-5.7%$5.13$1.75▼$37.59$1.03M0.861.03 million shs159,865 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHEPAHepion Pharmaceuticals0.00%-28.85%-7.50%-20.83%-99.85%NMTR9 Meters Biopharma0.00%0.00%0.00%-99.72%-81.82%SMFLSmart for Life0.00%-91.18%-95.16%-97.74%-99.96%SPRCSciSparc0.00%-18.83%-63.14%-73.15%-71.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHEPAHepion Pharmaceuticals 0.00N/AN/AN/ANMTR9 Meters Biopharma 0.00N/AN/AN/ASMFLSmart for Life 0.00N/AN/AN/ASPRCSciSparc 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHEPAHepion PharmaceuticalsN/AN/AN/AN/A$1.29 per shareN/ANMTR9 Meters BiopharmaN/AN/AN/AN/A$0.19 per shareN/ASMFLSmart for Life$11.11M0.00N/AN/A($17.10) per share0.00SPRCSciSparc$1.31M0.73N/AN/A$18.13 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHEPAHepion Pharmaceuticals-$48.93M-$219.00N/A∞N/AN/A-812.56%-207.31%11/12/2025 (Estimated)NMTR9 Meters Biopharma-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/ASMFLSmart for Life-$22.68MN/A0.00∞N/AN/AN/AN/AN/ASPRCSciSparc-$6.28MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHEPAHepion PharmaceuticalsN/AN/AN/AN/AN/ANMTR9 Meters BiopharmaN/AN/AN/AN/AN/ASMFLSmart for LifeN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHEPAHepion PharmaceuticalsN/A1.301.30NMTR9 Meters BiopharmaN/A0.590.59SMFLSmart for LifeN/AN/AN/ASPRCSciSparcN/A5.365.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHEPAHepion Pharmaceuticals17.24%NMTR9 Meters Biopharma22.34%SMFLSmart for Life28.39%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipHEPAHepion Pharmaceuticals0.06%NMTR9 Meters Biopharma2.40%SMFLSmart for Life31.71%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHEPAHepion Pharmaceuticals2011.44 million6.63 millionNo DataNMTR9 Meters Biopharma2014.34 million13.99 millionNo DataSMFLSmart for Life1107.09 million4.84 millionNot OptionableSPRCSciSparc4530,000527,000Not OptionableSMFL, NMTR, SPRC, and HEPA HeadlinesRecent News About These CompaniesSciSparc (NASDAQ:SPRC) Upgraded to "Sell" at Wall Street ZenSeptember 14 at 3:55 AM | americanbankingnews.comSciSparc Ltd. (NASDAQ:SPRC) Short Interest UpdateSeptember 12 at 4:13 AM | americanbankingnews.comSciSparc Shareholders Approve Merger with AutoMaxAugust 28, 2025 | tipranks.comSciSparc: AutoMax's Shareholders Approve Merger with SciSparcAugust 28, 2025 | globenewswire.comSciSparc Ltd. Shareholders Approve Merger with AutoMax Motors Ltd. to Expand into Automotive SectorAugust 28, 2025 | quiverquant.comQSciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in IsraelAugust 28, 2025 | globenewswire.comSciSparc Shareholders Approve Key Proposals at August MeetingAugust 26, 2025 | msn.comSciSparc Ltd. Reschedules Special Shareholder Meeting Due to Lack of QuorumAugust 25, 2025 | tipranks.comSciSparc Announces Patent Filing and Merger UpdatesAugust 8, 2025 | theglobeandmail.comSciSparc and Clearmind Publish Patent for Novel Obesity TherapyAugust 8, 2025 | tipranks.comSciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and ObesityAugust 7, 2025 | quiverquant.comQSciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood SugarAugust 7, 2025 | globenewswire.comSciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 31, 2025 | finanznachrichten.deSciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 30, 2025 | globenewswire.comClearmind Medicine files international patent application under PCTJuly 30, 2025 | msn.comSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver DiseaseJuly 30, 2025 | globenewswire.comSciSparc Ltd. Regains Nasdaq ComplianceJuly 22, 2025 | tipranks.comSciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price NotificationJuly 22, 2025 | globenewswire.comSciSparc Announces 1-for-21 Reverse Share Split - MorningstarJune 26, 2025 | morningstar.comMSciSparc Ltd. Adjourns Annual Meeting Due to Lack of QuorumJune 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMFL, NMTR, SPRC, and HEPA Company DescriptionsHepion Pharmaceuticals NASDAQ:HEPA$0.06 -0.02 (-29.03%) As of 09/12/2025 03:33 PM EasternHepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.9 Meters Biopharma NASDAQ:NMTR9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.Smart for Life NASDAQ:SMFL$0.0003 0.00 (-72.73%) As of 09/12/2025 10:32 AM EasternSmart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements under the Smart for Life brand; dietary supplements; and nutritional products, including whey protein isolate powder, tablet supplements for joint health, nitric oxide, post workout blends, Omega-3 supplements, and pre-workout supplements under the Sports Illustrated Nutrition brand for athletes and active lifestyle consumers. The company also provides various nutritional products, including antioxidant rich supplements, plant-based proteins, alkalizing nutrients, and weight management products. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Boca Raton, Florida.SciSparc NASDAQ:SPRC$1.81 -0.11 (-5.73%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.86 +0.04 (+2.49%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
